Related Experiment Videos
[Hypertrophic cardiomyopathy]
H Bundgaard1, O Havndrup, U Høst
1H:S Rigshospitalet, Hjertecentret, medicinsk afdeling B 2141.
Insights
Hypertrophic cardiomyopathy (HCM) is a genetic heart disease causing thickening of the heart muscle. Genetic diagnosis is crucial for understanding prognosis and improving patient management.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Context:
- Hypertrophic cardiomyopathy (HCM) is a progressive cardiac disease characterized by myocardial hypertrophy and disorganized muscle fibers.
- It presents with variable symptoms including angina, dyspnea, and syncope, and is a significant cause of sudden cardiac death in younger individuals.
Purpose:
- To review the genetic basis of hypertrophic cardiomyopathy.
- To highlight the role of genetic mutations in sarcomeric proteins and their impact on cardiac function.
- To emphasize the importance of genetic diagnosis in managing HCM.
Summary:
- HCM is primarily genetic (>60%), often inherited in an autosomal dominant pattern.
- Over 50 mutations in six genes affecting cardiac sarcomere proteins are linked to HCM.
- These mutations disrupt contractility and sarcomere assembly, leading to compensatory hypertrophy.
Impact:
- Advances in HCM management underscore the need for precise prognostic markers.
- Genetic testing offers a pathway to personalized risk assessment and treatment strategies.
- Identifying specific genetic mutations is vital for understanding disease progression and improving patient outcomes.
Abstract:
Hypertrophic cardiomyopathy is a heterogeneous, progressive disease with a variable age of debut. Hypertrophic cardiomyopathy is characterized by myocardial hypertrophy with a bizarre fibre disarray. Angina pectoris, dyspnoea and syncope are the most frequent symptoms. Hypertrophic cardiomyopathy is an important cause of sudden death, especially in children and young adults. The aetiology is genetic in more than 60% of the cases, with an autosomal dominant mode of inheritance. More than 50 different mutations involving six genes have so far been associated with the development of hypertrophic cardiomyopathy. These mutations are located to genes coding for several of the proteins in the cardiac sarcomere. The protein changes seem to compromise contractility as well as sarcomere assembly, thereby secondarily causing compensatory hypertrophy. The management of hypertrophic cardiomyopathy has been markedly improved within the last few years. This emphasizes the importance of determining prognostic markers in each patient. A specific genetic diagnosis may prove to be of major importance.